↓ Skip to main content

Active immunotherapy options for Alzheimer’s disease

Overview of attention for article published in Alzheimer's Research & Therapy, January 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

blogs
1 blog
twitter
2 X users
patent
2 patents
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
74 Dimensions

Readers on

mendeley
99 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Active immunotherapy options for Alzheimer’s disease
Published in
Alzheimer's Research & Therapy, January 2014
DOI 10.1186/alzrt237
Pubmed ID
Authors

Bengt Winblad, Ana Graf, Marie-Emmanuelle Riviere, Niels Andreasen, J Michael Ryan

Abstract

Alzheimer's disease (AD) is the most common cause of dementia and a major contributor to disability and dependency among older people. AD pathogenesis is associated with the accumulation of amyloid-beta protein (Aβ) and/or hyperphosphorylated tau protein in the brain. At present, current therapies provide temporary symptomatic benefit, but do not treat the underlying disease. Recent research has thus focused on investigating the molecular and cellular pathways and processes involved in AD pathogenesis to support the development of effective disease-modifying agents. In accordance with the existing Aβ-cascade hypothesis for AD pathogenesis, immunotherapy has been the most extensively studied approach in Aβ-targeted therapy. Both passive and active immunotherapies have been shown to effectively reduce Aβ accumulation and prevent downstream pathology in preclinical models. Following AN1792, second-generation active immunotherapies have shown promising results in terms of antibody response and safety. Comparatively, tau immunotherapy is not as advanced, but preclinical data support its development into clinical trials. Results from active amyloid-based immunotherapy studies in preclinical models indicate that intervention appears to be more effective in early stages of amyloid accumulation, highlighting the importance of diagnosing AD as early as possible and undertaking clinical trials at this stage. This strategy, combined with improving our understanding of the complex AD pathogenesis, is imperative to the successful development of these disease-modifying agents. This paper will review the active immunotherapies currently in development, including the benefits and challenges associated with this approach.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 99 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 1%
Egypt 1 1%
Unknown 97 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 23 23%
Student > Master 17 17%
Researcher 12 12%
Student > Ph. D. Student 9 9%
Student > Postgraduate 6 6%
Other 8 8%
Unknown 24 24%
Readers by discipline Count As %
Neuroscience 19 19%
Biochemistry, Genetics and Molecular Biology 14 14%
Medicine and Dentistry 13 13%
Agricultural and Biological Sciences 11 11%
Chemistry 4 4%
Other 10 10%
Unknown 28 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 September 2023.
All research outputs
#2,319,394
of 25,374,647 outputs
Outputs from Alzheimer's Research & Therapy
#483
of 1,465 outputs
Outputs of similar age
#26,396
of 322,830 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#4
of 13 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,465 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 26.6. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,830 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.